Animal-based pharmaceutical firm Ashish Life Sciences (ALS) has raised approximately $4 billion in funding. The investment was led by the Dutch venture arm of Eight Roads, with support from ALS . Anterra Capital will use the funding to scale its business in its existing markets and accelerate its plans to expand into Europe , Australia and Australia . The company produces a variety of products for bees and dairy, poultry and equine animals, including antiparasitics, ectoparasiticides and antibiotics.
Animal-based pharmaceutical firm Ashish Life Sciences (ALS) has raised $6.3m in funding. The investment was led by the Indian venture arm of Eight Roads, with support from Anterra Capital. ALS will use the funding to scale its business in its existing markets and accelerate its plans to expand into Europe, Australia and South Africa. The company produces a variety of products for bees and dairy, poultry and equine animals, including antiparasitics, ectoparasiticides and antibiotics.